Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the sequence as set forth in SEQ ID NO:1 to SEQ ID NO:15.

Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.

Abstract: The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis of breast cancer. The invention is more particularly based on the finding that specific biomarkers (olfactomedin-4, neudesin and desmoplakin) are abberantly expressed in the blood of breast cancer patients.

Abstract: Disclosed is a method for processing an asynchronous signal produced by a light sensor, the sensor having a pixel matrix disposed opposite a scene, the method including: receiving from the light sensor the asynchronous signal including, for each pixel of the matrix, successive events from the pixel; analysing the asynchronous signal using activity profiles as events are received in the asynchronous signal. The activity profile includes at least, for each pixel of the sensor, an activity value that decreases as a function of the time that has passed since the most recent event among the successive events from the pixel.

Abstract: The invention relates to a method of separating biological particles from the liquid containing same for purification, analysis and optionally diagnostic purposes. The inventive method comprises at least one step involving vertical filtration through a filter having a porosity that is adapted to the type of biological particles to be separated, such that said particles are retained by the filter. The invention is characterised in that: (i) the method involves the use of a filter comprising at least one basic filtration zone, whereby each basic filtration zone has a limited surface area; and (ii) the surface area of each basic filtration zone and the number of basic filtration zones are selected as a function of the type of liquid to be filtered, the type of biological particles to be separated and the volume of liquid to be filtered.

Abstract: The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of: (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity, (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, and (iii) establishing a daily dosage range per human adult per day wherein (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.

Abstract: The present invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.

Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.

Abstract: Method for determining the characteristics of a system for generating at least one pattern of light, the method comprising: a) providing a desired pattern of light, b) expressing the amplitude and the phase of the output pulse of the system as a function of the input laser pulse and in function of the characteristics of the system to obtain a calculated output pulse, the input laser pulse having a duration below or equal to 1 nanosecond, c) determining at least one characteristic of the system by minimizing a distance between the calculated output pulse and the desired output laser pulse.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates to a method for rapid generation of an infectious RNA virus that completely eliminates the need of constructing a full-length c DNA, which covers the entire viral genome, cloning and propagating such full length c DNA.

Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.

Abstract: An optical fiber mode scrambler adapted to give a determined bending to an optical fiber inserted in the mode scrambler, the mode scrambler having a general extension direction X, the mode scrambler having a morphology adapted to give the optical fiber a direction along X at the entry of the scrambler, and then to bend the fiber to bring the fiber substantially in the X, Y plan in the ?X and Y directions, before bringing the fiber in a rotation around the X axis substantially in the Y, Z plan in the anti clockwise direction for one full rotation, and then bending the fiber to bring the fiber substantially in the X, Y plan in the ?X and ?Y directions, and then bending the fiber to give the optical fiber a direction along X at the exit of the scrambler.

Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods for determining the ovarian reserve and ovarian function by determining the level of cell-free nucleic acids or the level of a miRNA species selected from miR_30_a or miR_140 or let_7_b or miR_191 or miR_320_a or miR_21 or miR_30_d or miR_574_3p. The method may also be used in predicting the efficacy of controlled ovarian hyperstimulation.

Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.

Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.

Abstract: An optical system for shaping a wavefront of an electric field of an input light beam to be projected into a target volume including a first optical element, a spatial light modulator used to control light distribution in at least one transverse plane in the target volume. An intermediate optical element located on an optical axis, after the first optical element on a trajectory of the light beam for modulating the phase or the amplitude of the electric field of the input light beam is included. A second optical element for modulating the phase or the amplitude of the electric field of the input light beam is used to control the axial position of the transverse plane in the target volume. The second optical element is situated on the optical axis after the at least one intermediate optical element on the trajectory of the light beam.

Abstract: The invention relates to modulating epileptogenicity in a brain of an epileptic patient. The method according to the invention comprises the steps of: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading said models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in said data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing said at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.